TapImmune Appoints Peter Hoang as President and Chief Executive Officer

JACKSONVILLE, Fla., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today announced that the... Biopharmaceuticals, Oncology, Personnel TapImmune, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news